Phase I/IIa Trial in Advanced Pancreatic Ductal Adenocarcinoma Treated with Cytotoxic Drug-Packaged, EGFR-Targeted Nanocells and Glycolipid-Packaged Nanocells

We assessed the safety and efficacy of an EGFR-targeted, super-cytotoxic drug, PNU-159682-packaged nanocells with α-galactosyl ceramide-packaged nanocells (E-EDV-D682/GC) in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had exhausted all treatment options. ENG9 was a first-in-ma...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 30; no. 2; pp. 304 - 314
Main Authors Ganju, Vinod, Marx, Gavin, Pattison, Scott, Amaro-Mugridge, Nancy B, Zhao, Jing-Ting, Williams, Bryan R G, MacDiarmid, Jennifer A, Brahmbhatt, Himanshu
Format Journal Article
LanguageEnglish
Published United States 17.01.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract We assessed the safety and efficacy of an EGFR-targeted, super-cytotoxic drug, PNU-159682-packaged nanocells with α-galactosyl ceramide-packaged nanocells (E-EDV-D682/GC) in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had exhausted all treatment options. ENG9 was a first-in-man, single-arm, open-label, phase I/IIa, dose-escalation clinical trial. Eligible patients had advanced PDAC, Eastern Cooperative Oncology Group status 0 to 1, and failed all treatments. Primary endpoints were safety and overall survival (OS). Of 25 enrolled patients, seven were withdrawn due to rapidly progressive disease and one patient withdrew consent. All 25 patients were assessed for toxicity, 24 patients were assessed for OS, which was also assessed for 17 patients completing one treatment cycle [evaluable subset (ES)]. Nineteen patients (76.0%) experienced at least one treatment-related adverse event (graded 1 to 2) resolving within hours. There were no safety concerns, dose reductions, patient withdrawal, or treatment-related deaths. Median OS (mOS) was 4.4 months; however, mOS of the 17 ES patients was 6.9 months [208 days; range, 83-591 days; 95.0% confidence interval (CI), 5.6-10.3 months] and mOS of seven patients who did not complete one cycle was 1.8 months (54 days; range, 21-72; 95.0% CI, 1.2-2.2 months). Of the ES, 47.1% achieved stable disease and one partial response. Ten subjects in the ES survived over 6 months, the longest 19.7 months. During treatments, 82.0% of the ES maintained stable weight. E-EDV-D682/GC provided significant OS, minimal side effects, and weight stabilization in patients with advanced PDAC. Advanced PDAC can be safely treated with super-cytotoxic drugs via EnGeneIC Dream Vectors to overcome multidrug resistance.
AbstractList We assessed the safety and efficacy of an EGFR-targeted, super-cytotoxic drug, PNU-159682-packaged nanocells with α-galactosyl ceramide-packaged nanocells (E-EDV-D682/GC) in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had exhausted all treatment options. ENG9 was a first-in-man, single-arm, open-label, phase I/IIa, dose-escalation clinical trial. Eligible patients had advanced PDAC, Eastern Cooperative Oncology Group status 0 to 1, and failed all treatments. Primary endpoints were safety and overall survival (OS). Of 25 enrolled patients, seven were withdrawn due to rapidly progressive disease and one patient withdrew consent. All 25 patients were assessed for toxicity, 24 patients were assessed for OS, which was also assessed for 17 patients completing one treatment cycle [evaluable subset (ES)]. Nineteen patients (76.0%) experienced at least one treatment-related adverse event (graded 1 to 2) resolving within hours. There were no safety concerns, dose reductions, patient withdrawal, or treatment-related deaths. Median OS (mOS) was 4.4 months; however, mOS of the 17 ES patients was 6.9 months [208 days; range, 83-591 days; 95.0% confidence interval (CI), 5.6-10.3 months] and mOS of seven patients who did not complete one cycle was 1.8 months (54 days; range, 21-72; 95.0% CI, 1.2-2.2 months). Of the ES, 47.1% achieved stable disease and one partial response. Ten subjects in the ES survived over 6 months, the longest 19.7 months. During treatments, 82.0% of the ES maintained stable weight. E-EDV-D682/GC provided significant OS, minimal side effects, and weight stabilization in patients with advanced PDAC. Advanced PDAC can be safely treated with super-cytotoxic drugs via EnGeneIC Dream Vectors to overcome multidrug resistance.
PURPOSEWe assessed the safety and efficacy of an EGFR-targeted, super-cytotoxic drug, PNU-159682-packaged nanocells with α-galactosyl ceramide-packaged nanocells (E-EDV-D682/GC) in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had exhausted all treatment options.PATIENTS AND METHODSENG9 was a first-in-man, single-arm, open-label, phase I/IIa, dose-escalation clinical trial. Eligible patients had advanced PDAC, Eastern Cooperative Oncology Group status 0 to 1, and failed all treatments. Primary endpoints were safety and overall survival (OS).RESULTSOf 25 enrolled patients, seven were withdrawn due to rapidly progressive disease and one patient withdrew consent. All 25 patients were assessed for toxicity, 24 patients were assessed for OS, which was also assessed for 17 patients completing one treatment cycle [evaluable subset (ES)]. Nineteen patients (76.0%) experienced at least one treatment-related adverse event (graded 1 to 2) resolving within hours. There were no safety concerns, dose reductions, patient withdrawal, or treatment-related deaths.Median OS (mOS) was 4.4 months; however, mOS of the 17 ES patients was 6.9 months [208 days; range, 83-591 days; 95.0% confidence interval (CI), 5.6-10.3 months] and mOS of seven patients who did not complete one cycle was 1.8 months (54 days; range, 21-72; 95.0% CI, 1.2-2.2 months). Of the ES, 47.1% achieved stable disease and one partial response. Ten subjects in the ES survived over 6 months, the longest 19.7 months. During treatments, 82.0% of the ES maintained stable weight.CONCLUSIONSE-EDV-D682/GC provided significant OS, minimal side effects, and weight stabilization in patients with advanced PDAC. Advanced PDAC can be safely treated with super-cytotoxic drugs via EnGeneIC Dream Vectors to overcome multidrug resistance.
Author Marx, Gavin
Brahmbhatt, Himanshu
Williams, Bryan R G
Ganju, Vinod
Amaro-Mugridge, Nancy B
MacDiarmid, Jennifer A
Pattison, Scott
Zhao, Jing-Ting
Author_xml – sequence: 1
  givenname: Vinod
  orcidid: 0000-0003-4713-7752
  surname: Ganju
  fullname: Ganju, Vinod
  organization: Peninsula and Southeast Oncology (PASO), Frankston Private Hospital, Frankston, Australia
– sequence: 2
  givenname: Gavin
  orcidid: 0000-0002-1016-6544
  surname: Marx
  fullname: Marx, Gavin
  organization: Sydney Adventist Hospital, Sydney, New South Wales, Australia
– sequence: 3
  givenname: Scott
  orcidid: 0000-0003-2089-7807
  surname: Pattison
  fullname: Pattison, Scott
  organization: EnGeneIC Ltd., Sydney, New South Wales, Australia
– sequence: 4
  givenname: Nancy B
  orcidid: 0000-0001-9933-0509
  surname: Amaro-Mugridge
  fullname: Amaro-Mugridge, Nancy B
  organization: EnGeneIC Ltd., Sydney, New South Wales, Australia
– sequence: 5
  givenname: Jing-Ting
  orcidid: 0009-0009-0139-5538
  surname: Zhao
  fullname: Zhao, Jing-Ting
  organization: EnGeneIC Ltd., Sydney, New South Wales, Australia
– sequence: 6
  givenname: Bryan R G
  orcidid: 0000-0002-4969-1151
  surname: Williams
  fullname: Williams, Bryan R G
  organization: Hudson Institute of Medical Research, Department of Molecular and Translational Science, Monash University Faculty of Medicine, Nursing and Health Sciences, Clayton, Victoria, Australia
– sequence: 7
  givenname: Jennifer A
  orcidid: 0000-0003-0394-9521
  surname: MacDiarmid
  fullname: MacDiarmid, Jennifer A
  organization: EnGeneIC Ltd., Sydney, New South Wales, Australia
– sequence: 8
  givenname: Himanshu
  orcidid: 0000-0003-4796-9890
  surname: Brahmbhatt
  fullname: Brahmbhatt, Himanshu
  organization: EnGeneIC Ltd., Sydney, New South Wales, Australia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37976042$$D View this record in MEDLINE/PubMed
BookMark eNpFkUtP3DAUha0KVB7tTyjysgsMfsRxshwFmI6E6AhN19bFsQeXTDy1E2D-DL8VRzy6upbOd67tc47QXh96i9APRs8Yk9U5o6oitBD8rGluCReEVZx9QYdMSkUEL-VePn8wB-gopb-UsoLR4is6EKpWJS34IXpZ3kOyeHG-WABeRQ8d9j2etY_QG9viZR7RwuANvhjNkNVZa_tgIBrfh81kyWoGn_xwj5vdEIbwPMFxXJMlmAdY2_YUX86vbskK4tpO7A3kDbbrEoa-xfNuZ0Lnt779NPwnvqF9B12y39_nMfpzdblqfpHr3_NFM7smhks1EMj_5VZxxyk4K52iQE3JmVSFa7ktDGdW1JUrCyqyKipZOqgLd8dcbXhO6Bj9fNu7jeHfaNOgNz5NL4DehjFpXtVMSc4Ez6h8Q00MKUXr9Db6DcSdZlRP1egpdj3FrnM1mgs9VZN9J-9XjHcb2366ProQr0UCjF0
Cites_doi 10.1097/MD.0000000000027591
10.1016/S1470-2045(17)30621-6
10.4251/wjgo.v12.i2.173
10.1371/journal.pone.0151832
10.3109/0284186X.2014.953257
10.1056/NEJMoa1011923
10.1101/gad.348523.121
10.1371/journal.pone.0144559
10.1200/EDBK_200643
10.1038/nature05907
10.1016/S1470-2045(17)30074-8
10.1016/j.amjsurg.2007.02.007
10.1016/S0140-6736(20)30974-0
10.1002/bjs.10063
10.1016/j.ejca.2008.10.026
10.1146/annurev-pathmechdis-031621-024600
10.1177/17588359211018539
10.1016/S1470-2045(10)70218-7
10.1002/cam4.621
10.1038/nbt.1547
10.1371/journal.pone.0152172
10.1200/JCO.2014.56.1894
10.1007/s11605-008-0505-z
10.1158/0008-5472.CAN-16-1201
10.1136/gutjnl-2012-302529
10.3390/cancers15020416
10.1245/s10434-014-4285-2
10.1164/rccm.201503-0461LE
10.1016/j.surg.2012.05.028
10.1016/j.clnu.2020.02.029
10.2174/1871520622666220408090541
10.1016/j.bpj.2016.03.040
10.1080/07357900701522653
10.1016/j.ccr.2014.06.003
10.1158/1078-0432.CCR-04-1845
10.1016/j.bmcl.2020.127640
10.1200/JCO.2015.61.6870
10.1002/jso.24623
10.1371/journal.pone.0193498
10.1016/j.jocn.2015.06.005
10.1038/s41598-019-53271-6
10.1007/s13105-022-00941-1
10.21037/jgo.2017.11.10
10.1016/j.ccr.2007.03.012
10.1007/s10637-013-0053-6
10.1158/1078-0432.CCR-06-3067
10.1016/j.ccell.2020.02.001
10.1093/annonc/mdv295
ContentType Journal Article
Copyright 2023 American Association for Cancer Research.
Copyright_xml – notice: 2023 American Association for Cancer Research.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1158/1078-0432.CCR-23-1821
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1557-3265
EndPage 314
ExternalDocumentID 10_1158_1078_0432_CCR_23_1821
37976042
Genre Clinical Trial, Phase II
Journal Article
Clinical Trial, Phase I
GrantInformation_xml – fundername: EnGeneIC Pty Ltd
GroupedDBID ---
18M
29B
2FS
34G
39C
476
53G
5GY
5RE
6J9
AAJMC
ABOCM
ACGFO
ACIWK
ACPRK
ADBBV
ADNWM
AENEX
AFHIN
AFOSN
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BR6
BTFSW
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBS
ECM
EIF
EJD
F5P
FRP
GX1
IH2
KQ8
L7B
LSO
NPM
OK1
P0W
P2P
QTD
RCR
RHF
RHI
RNS
SJN
TR2
WOQ
YKV
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c257t-a2652e72f20afe5f70a0c621574fd2e4c21e398f64035f73856fa94fb1f9c2043
ISSN 1078-0432
IngestDate Wed Jul 17 03:04:45 EDT 2024
Thu Nov 21 22:19:03 EST 2024
Sat Nov 02 12:27:57 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License 2023 American Association for Cancer Research.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c257t-a2652e72f20afe5f70a0c621574fd2e4c21e398f64035f73856fa94fb1f9c2043
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-2089-7807
0000-0001-9933-0509
0000-0003-4713-7752
0000-0002-1016-6544
0009-0009-0139-5538
0000-0002-4969-1151
0000-0003-4796-9890
0000-0003-0394-9521
PMID 37976042
PQID 2891752132
PQPubID 23479
PageCount 11
ParticipantIDs proquest_miscellaneous_2891752132
crossref_primary_10_1158_1078_0432_CCR_23_1821
pubmed_primary_37976042
PublicationCentury 2000
PublicationDate 2024-01-17
PublicationDateYYYYMMDD 2024-01-17
PublicationDate_xml – month: 01
  year: 2024
  text: 2024-01-17
  day: 17
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Clinical cancer research
PublicationTitleAlternate Clin Cancer Res
PublicationYear 2024
References Martin (2024011708131730500_bib42) 2015; 33
Liu (2024011708131730500_bib27) 2023; 79
Eisenhauer (2024011708131730500_bib17) 2009; 45
van Zandwijk (2024011708131730500_bib20) 2017; 18
Seymour (2024011708131730500_bib32) 2017; 18
Fearon (2024011708131730500_bib41) 2011; 12
Quintieri (2024011708131730500_bib12) 2005; 11
Cooper (2024011708131730500_bib49) 2015; 22
Borcoman (2024011708131730500_bib33) 2018; 38
Holte (2024011708131730500_bib13) 2020; 30
Jacobetz (2024011708131730500_bib30) 2013; 62
Terao (2024011708131730500_bib37) 2021; 100
Bernards (2024011708131730500_bib35) 2015; 54
Sherman (2024011708131730500_bib5) 2023; 18
Solomon (2024011708131730500_bib19) 2015; 10
Conroy (2024011708131730500_bib8) 2011; 364
Pecorelli (2024011708131730500_bib50) 2016; 103
Ali (2024011708131730500_bib47) 2016; 5
Lellouche (2024011708131730500_bib6) 2021; 13
MacDiarmid (2024011708131730500_bib31) 2016; 11
Di Costanzo (2024011708131730500_bib7) 2023; 15
Sagnella (2024011708131730500_bib11) 2020; 37
Pausch (2024011708131730500_bib45) 2012; 152
Ireland (2024011708131730500_bib22) 2016; 76
Bachmann (2024011708131730500_bib44) 2008; 12
Papageorgio (2024011708131730500_bib14) 2007; 25
Whittle (2024011708131730500_bib21) 2015; 22
Govindarajan (2024011708131730500_bib23) 2015
Gupta (2024011708131730500_bib26) 2017; 116
Mizrahi (2024011708131730500_bib2) 2020; 395
Beatty (2024011708131730500_bib4) 2021; 35
MacDiarmid (2024011708131730500_bib10) 2009; 27
Hendifar (2024011708131730500_bib40) 2018; 9
Borg (2024011708131730500_bib24) 2007; 448
Tumas (2024011708131730500_bib48) 2020; 39
Park (2024011708131730500_bib15) 2015; 8
Chiou (2024011708131730500_bib34) 2015; 33
Unnisa (2024011708131730500_bib16) 2022; 22
Sarantis (2024011708131730500_bib1) 2020; 12
Cerignoli (2024011708131730500_bib25) 2018; 13
Hendifar (2024011708131730500_bib39) 2016; 11
Siddiqui (2024011708131730500_bib38) 2007; 194
Lee (2024011708131730500_bib3) 2019; 9
DuFort (2024011708131730500_bib29) 2016; 110
Chauhan (2024011708131730500_bib28) 2014; 26
MacDiarmid (2024011708131730500_bib9) 2007; 11
Cousin (2024011708131730500_bib46) 2014; 32
Prado (2024011708131730500_bib43) 2007; 13
Ducreux (2024011708131730500_bib36) 2015; 26
Kao (2024011708131730500_bib18) 2015; 191
References_xml – volume: 100
  start-page: e27591
  year: 2021
  ident: 2024011708131730500_bib37
  article-title: Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer
  publication-title: Medicine
  doi: 10.1097/MD.0000000000027591
  contributor:
    fullname: Terao
– volume: 18
  start-page: 1386
  year: 2017
  ident: 2024011708131730500_bib20
  article-title: Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase I, open-label, dose-escalation study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(17)30621-6
  contributor:
    fullname: van Zandwijk
– volume: 12
  start-page: 173
  year: 2020
  ident: 2024011708131730500_bib1
  article-title: Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment, and immunotherapy
  publication-title: World J Gastrointest Oncol
  doi: 10.4251/wjgo.v12.i2.173
  contributor:
    fullname: Sarantis
– volume: 11
  start-page: e0151832
  year: 2016
  ident: 2024011708131730500_bib31
  article-title: Targeted doxorubicin delivery to brain tumors via minicells: proof of principle using dogs with spontaneously occurring tumors as a model
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0151832
  contributor:
    fullname: MacDiarmid
– volume: 54
  start-page: 403
  year: 2015
  ident: 2024011708131730500_bib35
  article-title: Ten weeks to live: a population-based study on treatment and survival of patients with metastatic pancreatic cancer in the south of the Netherlands
  publication-title: Acta Oncol
  doi: 10.3109/0284186X.2014.953257
  contributor:
    fullname: Bernards
– volume: 364
  start-page: 1817
  year: 2011
  ident: 2024011708131730500_bib8
  article-title: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1011923
  contributor:
    fullname: Conroy
– volume: 35
  start-page: 940
  year: 2021
  ident: 2024011708131730500_bib4
  article-title: The biological underpinnings of therapeutic resistance in pancreatic cancer
  publication-title: Genes Dev
  doi: 10.1101/gad.348523.121
  contributor:
    fullname: Beatty
– volume: 10
  start-page: e0144559
  year: 2015
  ident: 2024011708131730500_bib19
  article-title: A first-time-in-human phase I clinical trial of bispecific antibody-targeted, paclitaxel-packaged bacterial minicells
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0144559
  contributor:
    fullname: Solomon
– volume: 38
  start-page: 169
  year: 2018
  ident: 2024011708131730500_bib33
  article-title: Patterns of response and progression to immunotherapy
  publication-title: Am Soc Clin Oncol Educ Book
  doi: 10.1200/EDBK_200643
  contributor:
    fullname: Borcoman
– volume: 448
  start-page: 44
  year: 2007
  ident: 2024011708131730500_bib24
  article-title: CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor
  publication-title: Nature
  doi: 10.1038/nature05907
  contributor:
    fullname: Borg
– volume: 18
  start-page: e143
  year: 2017
  ident: 2024011708131730500_bib32
  article-title: iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(17)30074-8
  contributor:
    fullname: Seymour
– volume: 194
  start-page: 362
  year: 2007
  ident: 2024011708131730500_bib38
  article-title: Predictors of early mortality in veteran patients with pancreatic cancer
  publication-title: Am J Surg
  doi: 10.1016/j.amjsurg.2007.02.007
  contributor:
    fullname: Siddiqui
– volume: 8
  start-page: 8298
  year: 2015
  ident: 2024011708131730500_bib15
  article-title: EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma
  publication-title: Int J Clin Exp Pathol
  contributor:
    fullname: Park
– volume: 395
  start-page: 2008
  year: 2020
  ident: 2024011708131730500_bib2
  article-title: Pancreatic cancer
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30974-0
  contributor:
    fullname: Mizrahi
– volume: 103
  start-page: 434
  year: 2016
  ident: 2024011708131730500_bib50
  article-title: Effect of sarcopenia and visceral obesity on mortality and pancreatic fistula following pancreatic cancer surgery
  publication-title: Br J Surg
  doi: 10.1002/bjs.10063
  contributor:
    fullname: Pecorelli
– volume: 45
  start-page: 228
  year: 2009
  ident: 2024011708131730500_bib17
  article-title: New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2008.10.026
  contributor:
    fullname: Eisenhauer
– volume: 18
  start-page: 123
  year: 2023
  ident: 2024011708131730500_bib5
  article-title: Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance
  publication-title: Ann Rev Pathol
  doi: 10.1146/annurev-pathmechdis-031621-024600
  contributor:
    fullname: Sherman
– volume: 13
  start-page: 17588359211018539
  year: 2021
  ident: 2024011708131730500_bib6
  article-title: Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives
  publication-title: Ther Adv Med Oncol
  doi: 10.1177/17588359211018539
  contributor:
    fullname: Lellouche
– volume: 12
  start-page: 489
  year: 2011
  ident: 2024011708131730500_bib41
  article-title: Definition and classification of cancer cachexia: an international consensus
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(10)70218-7
  contributor:
    fullname: Fearon
– volume: 5
  start-page: 607
  year: 2016
  ident: 2024011708131730500_bib47
  article-title: Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens
  publication-title: Cancer Med
  doi: 10.1002/cam4.621
  contributor:
    fullname: Ali
– volume: 27
  start-page: 643
  year: 2009
  ident: 2024011708131730500_bib10
  article-title: Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.1547
  contributor:
    fullname: MacDiarmid
– volume: 11
  start-page: e0152172
  year: 2016
  ident: 2024011708131730500_bib39
  article-title: Influence of body mass index and albumin on perioperative morbidity and clinical outcomes in resected pancreatic adenocarcinoma
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0152172
  contributor:
    fullname: Hendifar
– volume: 33
  start-page: 90
  year: 2015
  ident: 2024011708131730500_bib42
  article-title: Diagnostic criteria for the classification of cancer-associated weight loss
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.56.1894
  contributor:
    fullname: Martin
– volume: 12
  start-page: 1193
  year: 2008
  ident: 2024011708131730500_bib44
  article-title: Cachexia worsens prognosis in patients with resectable pancreatic cancer
  publication-title: J Gastrointest Surg
  doi: 10.1007/s11605-008-0505-z
  contributor:
    fullname: Bachmann
– volume: 76
  start-page: 6851
  year: 2016
  ident: 2024011708131730500_bib22
  article-title: Chemoresistance in pancreatic cancer is driven by stroma-derived insulin-like growth factors
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-16-1201
  contributor:
    fullname: Ireland
– volume: 62
  start-page: 112
  year: 2013
  ident: 2024011708131730500_bib30
  article-title: Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
  publication-title: Gut
  doi: 10.1136/gutjnl-2012-302529
  contributor:
    fullname: Jacobetz
– volume: 15
  start-page: 416
  year: 2023
  ident: 2024011708131730500_bib7
  article-title: Optimizing first-line chemotherapy in metastatic pancreatic cancer: efficacy of FOLFIRINOX versus nab-paclitaxel plus gemcitabine
  publication-title: Cancers
  doi: 10.3390/cancers15020416
  contributor:
    fullname: Di Costanzo
– start-page: e53256
  year: 2015
  ident: 2024011708131730500_bib23
  article-title: An optimized method for isolating and expanding invariant natural killer T cells from mouse spleen
  publication-title: J Vis Exp
  contributor:
    fullname: Govindarajan
– volume: 22
  start-page: 2416
  year: 2015
  ident: 2024011708131730500_bib49
  article-title: Characterization of anthropometric changes that occur during neoadjuvant therapy for potentially resectable pancreatic cancer
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-014-4285-2
  contributor:
    fullname: Cooper
– volume: 191
  start-page: 1467
  year: 2015
  ident: 2024011708131730500_bib18
  article-title: A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201503-0461LE
  contributor:
    fullname: Kao
– volume: 152
  start-page: S81
  year: 2012
  ident: 2024011708131730500_bib45
  article-title: Cachexia but not obesity worsens the postoperative outcome after pancreatoduodenectomy in pancreatic cancer
  publication-title: Surgery
  doi: 10.1016/j.surg.2012.05.028
  contributor:
    fullname: Pausch
– volume: 39
  start-page: 3385
  year: 2020
  ident: 2024011708131730500_bib48
  article-title: Nutritional and immune impairments and their effects on outcomes in early pancreatic cancer patients undergoing pancreatoduodenectomy
  publication-title: Clin Nutr
  doi: 10.1016/j.clnu.2020.02.029
  contributor:
    fullname: Tumas
– volume: 22
  start-page: 3370
  year: 2022
  ident: 2024011708131730500_bib16
  article-title: Recent advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their role in the treatment of cancer: a review
  publication-title: Anticancer Agents Med Chem
  doi: 10.2174/1871520622666220408090541
  contributor:
    fullname: Unnisa
– volume: 110
  start-page: 2106
  year: 2016
  ident: 2024011708131730500_bib29
  article-title: Interstitial pressure in pancreatic ductal adenocarcinoma is dominated by a gel-fluid phase
  publication-title: Biophys J
  doi: 10.1016/j.bpj.2016.03.040
  contributor:
    fullname: DuFort
– volume: 25
  start-page: 647
  year: 2007
  ident: 2024011708131730500_bib14
  article-title: Epidermal growth factor receptor-targeted therapy for pancreatic cancer
  publication-title: Cancer Invest
  doi: 10.1080/07357900701522653
  contributor:
    fullname: Papageorgio
– volume: 26
  start-page: 14
  year: 2014
  ident: 2024011708131730500_bib28
  article-title: Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2014.06.003
  contributor:
    fullname: Chauhan
– volume: 11
  start-page: 1608
  year: 2005
  ident: 2024011708131730500_bib12
  article-title: Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-1845
  contributor:
    fullname: Quintieri
– volume: 30
  start-page: 127640
  year: 2020
  ident: 2024011708131730500_bib13
  article-title: Evaluation of PNU-159682 antibody drug conjugates (ADCs)
  publication-title: Bioorg Med Chem Lett
  doi: 10.1016/j.bmcl.2020.127640
  contributor:
    fullname: Holte
– volume: 33
  start-page: 3541
  year: 2015
  ident: 2024011708131730500_bib34
  article-title: Pseudoprogression and immune-related response in solid tumors
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2015.61.6870
  contributor:
    fullname: Chiou
– volume: 116
  start-page: 25
  year: 2017
  ident: 2024011708131730500_bib26
  article-title: Current and future therapies for advanced pancreatic cancer
  publication-title: J Surg Oncol
  doi: 10.1002/jso.24623
  contributor:
    fullname: Gupta
– volume: 13
  start-page: e0193498
  year: 2018
  ident: 2024011708131730500_bib25
  article-title: In vitro immunotherapy potency assays using real-time cell analysis
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0193498
  contributor:
    fullname: Cerignoli
– volume: 22
  start-page: 1889
  year: 2015
  ident: 2024011708131730500_bib21
  article-title: First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma
  publication-title: J Clin Neurosci
  doi: 10.1016/j.jocn.2015.06.005
  contributor:
    fullname: Whittle
– volume: 9
  start-page: 16971
  year: 2019
  ident: 2024011708131730500_bib3
  article-title: Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: a systematic review and meta-analysis
  publication-title: Sci Rep
  doi: 10.1038/s41598-019-53271-6
  contributor:
    fullname: Lee
– volume: 79
  start-page: 213
  year: 2023
  ident: 2024011708131730500_bib27
  article-title: Stroma-targeting strategies in pancreatic cancer: a double-edged sword
  publication-title: J Physiol Biochem
  doi: 10.1007/s13105-022-00941-1
  contributor:
    fullname: Liu
– volume: 9
  start-page: 17
  year: 2018
  ident: 2024011708131730500_bib40
  article-title: Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy
  publication-title: J Gastrointest Oncol
  doi: 10.21037/jgo.2017.11.10
  contributor:
    fullname: Hendifar
– volume: 11
  start-page: 431
  year: 2007
  ident: 2024011708131730500_bib9
  article-title: Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2007.03.012
  contributor:
    fullname: MacDiarmid
– volume: 32
  start-page: 382
  year: 2014
  ident: 2024011708131730500_bib46
  article-title: Low skeletal muscle is associated with toxicity in patients included in phase I trials
  publication-title: Invest New Drugs
  doi: 10.1007/s10637-013-0053-6
  contributor:
    fullname: Cousin
– volume: 13
  start-page: 3264
  year: 2007
  ident: 2024011708131730500_bib43
  article-title: Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-3067
  contributor:
    fullname: Prado
– volume: 37
  start-page: 354
  year: 2020
  ident: 2024011708131730500_bib11
  article-title: Cyto-immuno-therapy for cancer: a pathway elicited by tumor-targeted, tytotoxic drug-packaged bacterially derived nanocells
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.02.001
  contributor:
    fullname: Sagnella
– volume: 26
  start-page: v56
  year: 2015
  ident: 2024011708131730500_bib36
  article-title: Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdv295
  contributor:
    fullname: Ducreux
SSID ssj0014104
Score 2.4995127
Snippet We assessed the safety and efficacy of an EGFR-targeted, super-cytotoxic drug, PNU-159682-packaged nanocells with α-galactosyl ceramide-packaged nanocells...
PURPOSEWe assessed the safety and efficacy of an EGFR-targeted, super-cytotoxic drug, PNU-159682-packaged nanocells with α-galactosyl ceramide-packaged...
SourceID proquest
crossref
pubmed
SourceType Aggregation Database
Index Database
StartPage 304
SubjectTerms Adenocarcinoma - pathology
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
ErbB Receptors - genetics
Humans
Pancreatic Neoplasms - pathology
Title Phase I/IIa Trial in Advanced Pancreatic Ductal Adenocarcinoma Treated with Cytotoxic Drug-Packaged, EGFR-Targeted Nanocells and Glycolipid-Packaged Nanocells
URI https://www.ncbi.nlm.nih.gov/pubmed/37976042
https://search.proquest.com/docview/2891752132
Volume 30
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtMwGLbKkKbdTJzpOMhI3BV3qe0cfFmVrSvSUDU6qXeR68RbgCZVSBDjYXgJXpDfzqEtdBJw01ax46T9vv4H5z8g9NobSB88H048EXECKgD-UipQxBeR8E2WD1c2yve9d3bJ383deafzcyNqqSwWffV9Z17J_6AKxwBXkyX7D8i2i8IB-Az4wisgDK9_hfH0GnRQbwILTCayN6sacKS9YfNcfwpv1ihUvbelMmmPQxAzoL1ylaTZ0pwCo00A-uimyIrsm5mcl1dkKtUnEDaWASfj0wsys0HjMBskcmY2_KvyzuPPN0CmZJVE7SnrGZu276hJwlTm7vJeXWeo3Y8ey_RjaeNu4eai9VZ5bvXjWH5NWiJPZVEkda7YB1NdouXtUuYZOS-v2qbxVn3UvaXr3Q1qImJIlczZj2uJ7IIUpFVDiUZk149ykg3PuZK_rOpl_KdecAO7RWHKCXNG-6PRBaGMgHM12JwP8K6WlizMBzvNqQp__VaQuxm6g-6a6oumYcN43sYVmbhZXqeKwVWPd17zAO03q2zbQ7c4OdbYmd1Dh7WXgocV5e6jTpw-QPvndRzGQ_TDMg9PjoF32PIOJylueIfXvMMV7_A273DNO2x4h1ve4S3evcFbrMMtpzCwDu9g3XrGI3R5ejIbnZG60wdRoDIKIgFfGvtUU0fq2NW-Ix3lgTXqcx3RmCs6iJkItMcdBqMscD0tBdeLgRbKZHc_RntplsZPERZMLGJfgNfMNddMB44UWoFTE3mOkNrvon7ze4erqqBLaB1hNwgNVqHBKgSsQspCg1UXvWpQCUH0mq8h0zgrv4Q0EGB80wGjXfSkgqtdsoH36NaRZ-hgTfjnaK_Iy_gFGLjF4qUl1C-NGaLy
link.rule.ids 314,780,784,27924,27925
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phase+I%2FIIa+Trial+in+Advanced+Pancreatic+Ductal+Adenocarcinoma+Treated+with+Cytotoxic+Drug-Packaged%2C+EGFR-Targeted+Nanocells+and+Glycolipid-Packaged+Nanocells&rft.jtitle=Clinical+cancer+research&rft.au=Ganju%2C+Vinod&rft.au=Marx%2C+Gavin&rft.au=Pattison%2C+Scott&rft.au=Amaro-Mugridge%2C+Nancy+B&rft.date=2024-01-17&rft.eissn=1557-3265&rft.volume=30&rft.issue=2&rft.spage=304&rft_id=info:doi/10.1158%2F1078-0432.CCR-23-1821&rft_id=info%3Apmid%2F37976042&rft.externalDocID=37976042
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon